Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$210.3MCash on Hand
CF+ Cash Runway
Follow OCS by emailGet an email when OCS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about OCS, unsubscribe in one click. Privacy
📣 What OCS Says Is Next
this year · “This transaction comes at an opportune time, as Privosegtor is advancing rapidly through key regulatory milestones, including the ongoing PIONEER-1 registrational trial for optic neuritis and an expected IND submission for acute MS relapse later this year.”
Company press release, Aug 10, 2026 · SEC filing
late 2026 · “In 2025, following a successful FDA alignment meeting, we initiated the registrational PREDICT-1 trial in DED, with topline results anticipated around late 2026.”
Company press release, Apr 21, 2026 · SEC filing
Q4 2026 · “Topline results from PREDICT-1 are expected in Q4 2026.”
Company press release, Mar 3, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Financing Reported unaudited Q3 2026 results: net loss of CHF 18,236 thousand for the quarter and CHF 57,058 thousand for nine months, with cash and cash equivalents of CHF 66,292 thousand plus CHF 143,999 thousand in short-term financial assets at September 30, 2026. Form 6-K · SEC filing · Press release
Nov 3, 2026 ·
Financing Oculis amended its at-the-market sales agreement with Leerink Partners to raise capacity to $125,000,000 of ordinary shares, after selling $61,323,500 under the prior $100,000,000 program. Commissions are up to 3.0% of gross proceeds. Form 424B5 · SEC filing
Sep 30, 2026 ·
Leadership Lionel Carnot resigned from the Board of Directors effective September 30, 2026, after nearly a decade of service since 2017. The company says the departure is a personal decision and not a disagreement. The board will have eight members, and the vacancy can only be filled at a future shareholder meeting. Form 6-K · SEC filing · Press release
Aug 10, 2026 ·
Deal Oculis agreed to acquire Accure Therapeutics' worldwide rights to Privosegtor (ACT-01) and preclinical ACT-02 for $3.8 million cash plus up to 2,050,000 ordinary shares. The deal ends the existing Accure license and its milestone and royalty obligations. Closings are expected by February 28, 2027 and March 31, 2027. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 2/3 · Active Trial · A Clinical Study Evaluating Licaminlimab for Dry Eye Disease Registry primary completion date, not a results date
Dec 2027 · Phase 3 · Recruiting · Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not OCS's own candidates): Dexamethasone, Dexamethasone nanoparticles eye drops, OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
OCS holds $210.3M in cash and short-term investments and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OCS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.